Gold prices are declining due to a sharp rise in oil prices, which gained 3.5% on fears of renewed U.S. and Israeli military action against Iran. This geopolitical risk is pushing oil higher and may prompt the Federal Reserve to maintain a hawkish stance on interest rates. Meanwhile, the U.S. dollar is strengthening supported by rising Treasury yields and strong economic data, further pressuring gold. Silver and platinum are also falling, with silver testing new lows and platinum approaching key support levels, reflecting broad weakness in precious metals amid these market dynamics.
Gold prices are testing $4000 amid ongoing pullbacks, providing context for precious metals market dynamics. For readers following US stocks on Pluang, here is the market snapshot as of Oct 24, 2026 01:21 WIB: out of 150 priced US stocks, 49 rose and 101 fell. Notable movers include Schlumberger NV (SLB) at USD 53.16 with a 1-day change of +7.29% and Pluang order activity of 83% Sell / 17% Buy, AT&T Inc. (T) at USD 21.23 down 6.62% with 41% Sell / 59% Buy, and Halliburton Company (HAL) at USD 34.91 up 5.18% with 86% Sell / 14% Buy.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
